(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.
Ars Pharmaceuticals's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast SPRY's revenue for 2024 to be $1,126,823,063, with the lowest SPRY revenue forecast at $1,126,823,063, and the highest SPRY revenue forecast at $1,126,823,063. On average, 1 Wall Street analysts forecast SPRY's revenue for 2025 to be $3,155,104,575, with the lowest SPRY revenue forecast at $3,155,104,575, and the highest SPRY revenue forecast at $3,155,104,575.
In 2026, SPRY is forecast to generate $2,794,521,195 in revenue, with the lowest revenue forecast at $2,794,521,195 and the highest revenue forecast at $2,794,521,195.